- Home
- RNAZ vs CYCN Comparison
RNAZ vs CYCN Comparison
Compare RNAZ & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- CYCN
- Stock Information
- Founded
- RNAZ 2016
- CYCN 2018
- Country
- RNAZ United States
- CYCN United States
- Employees
- RNAZ N/A
- CYCN N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- CYCN Health Care
- Exchange
- RNAZ Nasdaq
- CYCN Nasdaq
- Market Cap
- RNAZ 8.7M
- CYCN 7.6M
- IPO Year
- RNAZ 2021
- CYCN N/A
- Fundamental
- Price
- RNAZ $13.77
- CYCN $2.14
- Analyst Decision
- RNAZ Strong Buy
- CYCN
- Analyst Count
- RNAZ 1
- CYCN 0
- Target Price
- RNAZ $280.00
- CYCN N/A
- AVG Volume (30 Days)
- RNAZ 421.5K
- CYCN 76.7K
- Earning Date
- RNAZ 11-13-2025
- CYCN 11-13-2025
- Dividend Yield
- RNAZ N/A
- CYCN N/A
- EPS Growth
- RNAZ N/A
- CYCN N/A
- EPS
- RNAZ N/A
- CYCN N/A
- Revenue
- RNAZ N/A
- CYCN $2,174,000.00
- Revenue This Year
- RNAZ N/A
- CYCN N/A
- Revenue Next Year
- RNAZ N/A
- CYCN N/A
- P/E Ratio
- RNAZ N/A
- CYCN N/A
- Revenue Growth
- RNAZ N/A
- CYCN N/A
- 52 Week Low
- RNAZ $6.15
- CYCN $1.27
- 52 Week High
- RNAZ $643.94
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- RNAZ 55.86
- CYCN 39.56
- Support Level
- RNAZ $12.11
- CYCN $2.03
- Resistance Level
- RNAZ $15.49
- CYCN $2.46
- Average True Range (ATR)
- RNAZ 1.74
- CYCN 0.14
- MACD
- RNAZ -0.13
- CYCN -0.03
- Stochastic Oscillator
- RNAZ 23.76
- CYCN 20.74
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.